One CLL subject received bendamustine plus rituximab as second-line therapy after failure of fludarabine plus alemtuzumab; an FL patient was treated with rituximab plus higher dose of bendamustine after partial response to rituximab plus bendamustine at 70 mg/m2; the two subjects with Sézary syndrome received bendamustine alone as third-line therapy after failure of interferon-based regimens, while one MZL subject received RB after nonresponsiveness to chlorambucil first and R-FluCy later. The gene discussed is RB1; the disease is B-cell chronic lymphocytic leukemia.